DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LEVONORGESTREL AND ETHINYL ESTRADIOL

Clinical Trials for Levonorgestrel And Ethinyl Estradiol

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00117273	A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens	Completed	Duramed Research	Phase 3	This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy, reproductive-aged women using three different regimens of oral contraceptives (OCs). Two extended regimen OCs, Seasonale (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of placebo), and Seasonique (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of ethinyl estradiol 0.01 mg), and a 28-day regimen OC, Portia (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 21 days followed by 7 days of placebo).
NCT00128934	Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	The purpose of this study is to determine whether levonorgestrel (LNG)/ethinyl estradiol (EE) is effective in treating the symptoms of severe premenstrual syndrome (PMS).
NCT00161681	Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	The purpose of this study is to determine whether LNG/EE is effective in the treatment of menstrual cycle related symptoms.
NCT00195559	Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	The purpose of this study is to determine whether Levonorgestrel/Ethinyl Estradiol (LNG/EE) is effective in treating the symptoms of severe Premenstrual Dysphoric Disorder.
NCT00204451	Human Ovarian Follicular Dynamics and Emergency Contraception	Completed	Canadian Institutes of Health Research (CIHR)	Phase 4	The researchers hypothesize that emergency contraception (EC) will initiate the changes associated with atresia or ovulatory failure at all stages of follicular development and that the image attributes associated with atresia will be similar regardless of the diameter of the dominant follicle when ovarian suppression is initiated. Second, changes associated with atresia may be observed, but ovulation of the dominant follicle is unimpeded.
NCT00204451	Human Ovarian Follicular Dynamics and Emergency Contraception	Completed	University of Saskatchewan	Phase 4	The researchers hypothesize that emergency contraception (EC) will initiate the changes associated with atresia or ovulatory failure at all stages of follicular development and that the image attributes associated with atresia will be similar regardless of the diameter of the dominant follicle when ovarian suppression is initiated. Second, changes associated with atresia may be observed, but ovulation of the dominant follicle is unimpeded.
Trial ID	Title	Status	Sponsor	Phase	Summary